SPY328.73+5.23 1.62%
DIA271.70+3.60 1.34%
IXIC10,913.56+241.30 2.26%

AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference

AzurRx BioPharma, Inc.

Benzinga · 01/10/2020 10:43

AzurRx BioPharma, Inc. (NASDAQ: AZRX) announced it will present new data from five patients enrolled in its Phase 2 study for its lead development candidate MS1819-SD at the 2020 Biotech Showcase Conference being held at the Hilton San Francisco Union Square Hotel (Yosemite C - Ballroom Level)on Monday, January 13that 3:00 p.m. Pacific Time.

The Phase 2 clinical trial is designed to investigate the safety, tolerability and efficacy of escalating doses of MS1819-SD, in conjunction with a stable dose of PERTs, in order to increase the coefficient of fat absorption (CFA) and relieve abdominal symptoms in Cystic Fibrosis (CF) patients suffering from severe exocrine pancreatic insufficiency (EPI). Patients enrolled in the study continue to experience clinical symptoms of fatmalabsorption,despite efforts to control their symptoms with commercially-available PERTs.

Data from the initial five patients showed positive trends regarding the primary efficacy endpoint of CFA improvement with no adverse events reported. Trends were also positive in the secondary endpoints of improvements in body weight and stool consistency and reductions in the number of bowel movements and the incidence of steatorrhea. Additionally, multiple patients reported experiencing less abdominal pain while being on the combination therapy.

Dr. James Pennington, Chief Medical Officer of AzurRx, will provide an overview of the new data and the Company's clinical development programs during a live presentation scheduled for 3:00 p.m. at the Biotech Showcase Conference. After the presentation, Dr. Pennington and James Sapirstein, the Company's Chief Executive Officer, will be available for one-on-one meetings with investors registered for the conference.